Irene Ghobrial, MD - Home | Facebook
ASH 2022: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
Eileen Mary BOYLE | PostDoc /MD | MD/PhD | NYU Langone Medical Center, New York City | NYUMC | Cancer Institute | Research profile
Forimtamig's Effect on T-cells in Relapsed Myeloma Patients
Antibody-drug Conjugates in Relapsed/Refractory Multiple Myeloma: from Bench to Bedside - Springer Healthcare IME
Dr. Karma Salem, MD – Atlanta, GA | Radiology
Salomon Manier
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber 09/27 by HealthTree Podcast for MM | Health
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis
Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in Waldenström Macroglobulinemia
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma | PLOS ONE
Team : Factors of persistence of leukemic cells - Canther
ASH 2022: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
Sequencing multiple myeloma using blood tests - ecancer
Narrow subset of cells is responsible for metastasis in multiple myeloma, study finds - Dana-Farber Cancer Institute | Boston, MA
Post-Congress webinars – International Academy for Clinical Hematology (IACH)
Sequencing BCMA-targeted agents in multiple myeloma | VJHemOnc
ide-cel and neurotoxicity | Int'l Myeloma Foundation
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results - ScienceDirect
ASH 2022: Multiple Myeloma Highlights - The ASCO Post
Springer Healthcare IME Independent, CME Accredited Symposium – The 9th COMy World Congress
Post-Congress webinars – International Academy for Clinical Hematology (IACH)
Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment - BroadcastMed
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant | Nature Communications
MagnetisMM-3 Results: Elranatamab in Relapsed Myeloma | Int'l Myeloma Fn
Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber by Myeloma Crowd Radio | Mixcloud
Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma | PLOS ONE
Dr.MHB (@DrMHB1) / Twitter
Knowing and Finding the enemy - Roswell Park Comprehensive Cancer Center
